BioCentury | Jul 20, 2018
Company News

PTC acquiring CNS gene therapy play Agilis

...2-6% for Agilis' programs for Friedreich ataxia and Angelman syndrome. Agilis’ lead candidate, GT-AADC (formerly AGIL-AADC...
...Biotherapeutics Inc., Cambridge, Mass. PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Business: Neurology Jaime De Leon AADC gene therapy, AGIL-AADC...
BioCentury | Jul 19, 2018
Company News

PTC acquiring CNS gene therapy play Agilis

...2-6% for Agilis' programs for Friedreich ataxia and Angelman syndrome. Agilis’ lead candidate, GT-AADC (formerly AGIL-AADC...
...Deal, CEO and Financing” ). The deal is expected to close this quarter. Jaime De Leon AADC gene therapy, AGIL-AADC...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

...1012 vg/kg per limb, total 2.4 x 1012 vg/kg Ph I/II AAV2 Agilis Biotherapeutics Inc. AGIL-AADC...
BioCentury | Nov 22, 2016
Clinical News

AGIL-AADC regulatory update

...FDA granted rare pediatric disease designation to Agilis’ AGIL-AADC to treat Aromatic L-Amino Acid Decarboxylase (AADC...
...Agilis Biotherapeutics LLC , Cambridge, Mass. Product: AGIL-AADC Business: Neurology Alicia Parker AADC gene therapy Agilis Biotherapeutics LLC Dopa decarboxylase (DDC) (AADC) AGIL-AADC...
BioCentury | Jun 18, 2012
Clinical News

AADC gene therapy: Phase I data

...Data were published in Science Translational Medicine. National Taiwan University Hospital , Taipei, Taiwan Product: AADC gene therapy...
Items per page:
1 - 5 of 5